The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer
Introduction: The PRIMARY score of the PROMISE-V2 criteria for primary staging of prostate cancer (PCa) and its relationship with the maximum standardized uptake value normalized to lean body mass (SULmax) have not been evaluated. This study determined the relationship between the SULmax value in [1...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2024-10-01
|
| Series: | Journal of the Mexican Federation of Radiology and Imaging |
| Online Access: | https://www.jmexfri.com/frame_eng.php?id=120 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557067873124352 |
|---|---|
| author | J. Antonio Serna-Macias M. Lourdes Garcia-Colmenero Emilly A. Cortes-Mancera E. David Muñoz-Carpio Mixel Z. Baltierra-Hernandez |
| author_facet | J. Antonio Serna-Macias M. Lourdes Garcia-Colmenero Emilly A. Cortes-Mancera E. David Muñoz-Carpio Mixel Z. Baltierra-Hernandez |
| author_sort | J. Antonio Serna-Macias |
| collection | DOAJ |
| description | Introduction: The PRIMARY score of the PROMISE-V2 criteria for primary staging of prostate cancer (PCa) and its relationship with the maximum standardized uptake value normalized to lean body mass (SULmax) have not been evaluated. This study determined the relationship between the SULmax value in [18F]PSMA-1007 PET/CT and the PROMISE-V2 PRIMARY score in patients with untreated PCa in primary staging. Material and Methods: This cross-sectional study included patients with PCa in primary staging. The SULmax value [18F]PSMA-1007 PET/CT of the intraprostatic lesion was recorded, and the PRIMARY score was assessed based on the pattern of affected prostate zones (peripheral, transitional, or central) and the distribution of prostate-specific membrane antigen (PSMA) uptake (focal or diffuse). Lymph node (pelvic or extrapelvic) spread and metastasis (bone, lung, and/ or brain) were determined. Results: Fifty-five patients with PCa at primary staging were included. The SULmax value of an intraprostatic tumor in PRIMARY score 2 was 5.15 ± 0.54 g/mL; in PRIMARY score 3, 7.11 g/mL; in PRIMARY score 4, 8.31 ± 1.92 g/mL, and in PRIMARY score 5, 22.64 ± 7.77 (p < 0.001). The SULmax value of [18F]PSMA increased in direct association with the PRIMARY score in cases with an intraprostatic tumor (11.49 ± 6.69 g/mL (p < 0.001) and an intraprostatic tumor + pelvic lymph nodes (15.17 ± 9.72 g/mL). In contrast, cases with extrapelvic lymph nodes or metastases (bone, brain, or lung) had lower SULmax values (12.43 ± 8.73 g/mL) (p < 0.001). Conclusion: Our study showed an association between the SULmax value and the PRIMARY score according to the affected anatomical zone, the expression patterns and a SULmax > 12 g/mL. The expression of PSMA uptake in the local tumor was highest in the pattern of focal involvement in the peripheral zone (PZ) as long as the disease was confined to the pelvis.
|
| format | Article |
| id | doaj-art-0cb1e6c41573446080f7cd3e8d84613a |
| institution | Kabale University |
| issn | 2938-1215 2696-8444 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Permanyer |
| record_format | Article |
| series | Journal of the Mexican Federation of Radiology and Imaging |
| spelling | doaj-art-0cb1e6c41573446080f7cd3e8d84613a2025-01-06T22:24:19ZengPermanyerJournal of the Mexican Federation of Radiology and Imaging2938-12152696-84442024-10-013410.24875/JMEXFRI.M24000091The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancerJ. Antonio Serna-Macias0M. Lourdes Garcia-Colmenero1Emilly A. Cortes-Mancera2E. David Muñoz-Carpio3Mixel Z. Baltierra-Hernandez4Postgraduate of High Specialty in Positron Emission Tomography/Computed Tomography, Universidad Nacional Autonoma de Mexico, Mexico City; Radiology and Imaging Service, Hospital Angeles Pedregal, Mexico City; MexicoDepartamento de Imagen Molecular – PET/CT, CID Centro de Imagen y Diagnostico, Guadalajara, Jalisco, MéxicoServicio de Medicina Nuclear, Hospital Central Sur de Alta Especialidad, Petroleos Mexicanos. Mexico City, MexicoDepartamento de Atencion a la Salud, Unidad Xochimilco, Universidad Autonoma Metropolitana. Mexico City, MexicoDepartamento de Atencion a la Salud, Unidad Xochimilco, Universidad Autonoma Metropolitana. Mexico City, MexicoIntroduction: The PRIMARY score of the PROMISE-V2 criteria for primary staging of prostate cancer (PCa) and its relationship with the maximum standardized uptake value normalized to lean body mass (SULmax) have not been evaluated. This study determined the relationship between the SULmax value in [18F]PSMA-1007 PET/CT and the PROMISE-V2 PRIMARY score in patients with untreated PCa in primary staging. Material and Methods: This cross-sectional study included patients with PCa in primary staging. The SULmax value [18F]PSMA-1007 PET/CT of the intraprostatic lesion was recorded, and the PRIMARY score was assessed based on the pattern of affected prostate zones (peripheral, transitional, or central) and the distribution of prostate-specific membrane antigen (PSMA) uptake (focal or diffuse). Lymph node (pelvic or extrapelvic) spread and metastasis (bone, lung, and/ or brain) were determined. Results: Fifty-five patients with PCa at primary staging were included. The SULmax value of an intraprostatic tumor in PRIMARY score 2 was 5.15 ± 0.54 g/mL; in PRIMARY score 3, 7.11 g/mL; in PRIMARY score 4, 8.31 ± 1.92 g/mL, and in PRIMARY score 5, 22.64 ± 7.77 (p < 0.001). The SULmax value of [18F]PSMA increased in direct association with the PRIMARY score in cases with an intraprostatic tumor (11.49 ± 6.69 g/mL (p < 0.001) and an intraprostatic tumor + pelvic lymph nodes (15.17 ± 9.72 g/mL). In contrast, cases with extrapelvic lymph nodes or metastases (bone, brain, or lung) had lower SULmax values (12.43 ± 8.73 g/mL) (p < 0.001). Conclusion: Our study showed an association between the SULmax value and the PRIMARY score according to the affected anatomical zone, the expression patterns and a SULmax > 12 g/mL. The expression of PSMA uptake in the local tumor was highest in the pattern of focal involvement in the peripheral zone (PZ) as long as the disease was confined to the pelvis. https://www.jmexfri.com/frame_eng.php?id=120 |
| spellingShingle | J. Antonio Serna-Macias M. Lourdes Garcia-Colmenero Emilly A. Cortes-Mancera E. David Muñoz-Carpio Mixel Z. Baltierra-Hernandez The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer Journal of the Mexican Federation of Radiology and Imaging |
| title | The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer |
| title_full | The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer |
| title_fullStr | The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer |
| title_full_unstemmed | The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer |
| title_short | The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer |
| title_sort | promise v2 primary score and sulmax 18f psma 1007 pet ct in primary staging of prostate cancer |
| url | https://www.jmexfri.com/frame_eng.php?id=120 |
| work_keys_str_mv | AT jantoniosernamacias thepromisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer AT mlourdesgarciacolmenero thepromisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer AT emillyacortesmancera thepromisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer AT edavidmunozcarpio thepromisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer AT mixelzbaltierrahernandez thepromisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer AT jantoniosernamacias promisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer AT mlourdesgarciacolmenero promisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer AT emillyacortesmancera promisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer AT edavidmunozcarpio promisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer AT mixelzbaltierrahernandez promisev2primaryscoreandsulmax18fpsma1007petctinprimarystagingofprostatecancer |